Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cognetivity Neurosciences Ltd C.CGN

Alternate Symbol(s):  CGNSF

Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical and commercial environments and other neurological conditions. The Company’s CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help... see more

CSE:CGN - Post Discussion

Cognetivity Neurosciences Ltd > Sina expects $100M in revenues by 2023/24
View:
Post by GoCGNGo on Nov 23, 2021 6:24pm

Sina expects $100M in revenues by 2023/24

https://capital.com/medical-technology-firm-fda-approval-unlocks-us-markets
Comment by GoCGNGo on Nov 23, 2021 8:04pm
Assuming a 100% CAGR, 2022 revenues would be around $25-50M, 2023 $50-100M, and 2024 $100-200M.
Comment by GoCGNGo on Nov 23, 2021 8:05pm
What would the PE ratio be for a company growing at a 100% CAGR?
Comment by tinkvid on Nov 25, 2021 10:52am
It will be taken out long before it were to reach those revenues! Apple, Big Pharma..... 
Cognetivity Neurosciences Ltd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities